DDAVP for bleeding prophylaxis in patients undergoing kidney biopsy procedures: A randomized controlled trial

outcome of DDAVP adminiter prior to kidney biopsy for bleeding prevention

Status

Unknown

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220321004

Enrollment

160

Registered

2022-03-21

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the efficacy of DDAVP for bleeding prevention in kidney biopsy DDAVP, Kidney biopsy, Bleeding, native kidney disease biopsy

Interventions

DDAVP 0.3 mcg/kg/dose intravenous prior to kidney biopsy add on standard bleeding prevention

Experimental Drug

DDAVP

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Native kidney biopsy, GFR> 30 ml/min/1.73m2 (Thai CKD-EPI)

Exclusion criteria

Exclusion criteria: Kidney Transplant Single kidney, hydronephrosis, small kidney < 8 cm, multiple cystic kidney Bleeding tendency (plt<120,000/u, INR > 1.5,patients who do not withdraw antiplatelet or anticoagulant ) Hyponatremia BMI > 35 kg/ m2 Pregnancy Patient who did not agree

Design outcomes

Primary

Measure	Time frame
Bleeding composite outcome 1 day after kidney biopsy Hb drop more than 1 g/dl, hematoma size more than 2 cm, persistent gross hematuria or urinary tract obstruction, major bleeding outcome	—

Secondary

Measure	Time frame
size of perinephric hematoma, AKI, hospital stay, adverse outcome of DDAVP 1 day size of perinephric hematoma, AKI, hospital stay, adverse outcome of DDAVP; hyponatremia, thrombotic event, composite bleeding outcome in GFR more than 60 ml/min/1.73m2	—

Countries

Thailand

Contacts

Public ContactPunnawit Laungchuaychok

Medicine

punnawit@nmu.ac.th022443000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026